SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Five children from two non-consanguineous Asian families with juvenile-onset hexosaminidase deficiency are presented. Two have juvenile Tay-Sachs disease with hexosaminidase A deficiency and three have juvenile Sandhoff disease with hexosaminidase A and B deficiency. The contributing factors in the spectrum of the hexosaminidase deficiency disease are outlined, and previously reported cases of late-onset Tay-Sachs and Sandhoff disease are reviewed. The heterogeneity of the effects of hexosaminidase deficiency is discussed, with the recommendation that the diagnosis be considered, in its various forms, when there is no other obvious explanation.
The insulin-like growth factor-II/mannose-6-phosphate receptor binds two classes of ligands, IGF-II and lysosomal enzymes containing the mannose-6-phosphate recognition marker. To study the interaction of the two classes of ligands at the receptor level, we have isolated 'high uptake' forms of lysosomal enzymes containing mannose-6-phosphate that had been radiolabeled biosynthetically using a tissue culture model: Tay-Sachs disease fibroblasts were incubated in medium containing [3H]mannose, ammonium chloride and mannose-6-phosphate. Under the conditions of these experiments, the Tay-Sachs disease fibroblasts synthesized and secreted radiolabeled hexosaminidase B, as confirmed by measuring enzymatic activity of cell-conditioned medium. The enzyme secreted was recognized by antibodies raised against purified hexosaminidase A and B but not by nonimmune control sera in Western blotting and immunoprecipitation experiments. The radiolabeled cell-conditioned medium was partially purified by ion-exchange chromatography on a DEAE-Sephadex column. When partially purified [3H]hexosaminidase B was incubated with rat C6 glial cells which express large numbers of IGF-II/mannose-6-phosphate receptors, the enzyme was taken up specifically via the IGF-II/mannose-6-phosphate receptor as evidenced by carbohydrate competition experiments. The specific uptake of the radiolabeled lysosomal enzyme was partially inhibited by IGF-II and an antibody against the IGF-II/mannose-6-phosphate receptor (No. 3637). We conclude that the cellular uptake of a biosynthetically labeled lysosomal enzyme, hexosaminidase B, is partially inhibited by IGF-II. We hypothesize that IGF-II might be capable of modulating lysosomal pathways in vivo.
Aberrant crypt foci (ACF), consisting of morphologically irregular crypts, are thought to be precancerous lesions for colon cancers. For their molecular analysis, it is necessary to avoid contamination with adjacent normal crypts and stromal cells. Decreased hexosaminidase activity in ACF, which has been histochemically demonstrated, was used in the present study to classify isolated crypts in combination with morphological changes. The length, rim diameter, and width (average SD, microm) of hexosaminidase-positive (Hex + ) crypts were 238.6 +/- 40.4, 89.5 +/- 22.9, and 57.6 +/- 14.0, respectively. For hexosaminidase-negative (Hex - ) crypts, the values were 314.4 +/- 77.8, 140.3 +/- 45.7, and 97.3 +/- 34.7, the width being 1.69 times greater (P < 0.0001). Crypts wider than 115 microm (approximately 2 times the average size of Hex + crypts) were all from ACF, judging from hexosaminidase staining. To analyze transcription levels of Hex alpha and beta subunits (Hexa and Hexb, respectively), real-time relative quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed using the LightCycler system. In aberrant crypts, both Hexa and Hexb were significantly down-regulated to 0.266 (P < 0.002) and 0.131 (P < 0.001) units, respectively, compared with those in morphologically normal crypts, with beta-actin as the internal standard. This decrease could be a molecular marker for precancerous enzyme-altered ACF.
The isolation and purification of human kidney hexosaminidases A and B was carried out. Regulation of the supramolecular organization and catalytic activity of hexosaminidases was investigated in the bis(2-ethylhexyl)sulphosuccinate reversed micellar system modeling the enzyme microenvironment in the lysosomes. It was shown that hexosaminidases A and B associate forming 280-300-kDa dimeric complexes under these conditions. At pH 4.75, the hexosaminidases A and B can be isolated from kidney tissue only in the form of this complex.
Isolation and purification on human kidney hexosaminidases A and B (EC 3.2.1.30) were carried out. The regulation of the supramolecular organization and catalytic activity of the hexosaminidases in the AOT reversed micellar system modelling the enzyme microenvironment in the lysosomes, were investigated. It was found that under these conditions hexosaminidases A and B associate to form a 280-300 kDa dimeric complex. At pH 4.75 hexosaminidases A and B can be isolated from kidney tissue only within the composition of the complex.
Competition experiments were carried out on the hydrolysis of different substrates by beta-hexosaminidase A isolated from human liver. The results show that ganglioside GM2 in the presence of the GM2 activator protein and a new synthetic substrate, 4-methylumbelliferyl-beta-N-acetylglucosaminide 6-sulfate, are hydrolyzed at the same active site on the alpha subunit of beta-hexosaminidase A, whereas 4-methylumbelliferyl-beta-N-acetylglucosaminide is degraded predominantly by a different active site on the beta-subunit. This finding provides for the first time a possible molecular basis for the observation that, in variant B1 of the GM2 gangliosidoses, beta-hexosaminidase A has lost its activity toward GM2 ganglioside and the sulfated artificial substrate while being still able to hydrolyze the unsulfated artificial substrate at a normal rate. Furthermore, the finding that the GM2 activator protein inhibits the degradation of the sulfated substrate by beta-hexosaminidases A and S indicates that the alpha subunit common to both isoenzymes might provide a binding site for the activator protein.
The lysosomal hydrolase beta-hexosaminidase (beta-N-acetylhexosaminidase, EC 3.2.1.52) exists as two major isozymes in normal human tissue: an acidic A-form and a basic B-form. There are also minor forms of intermediate pI known as I-forms. Increases in one or more of these intermediates have been associated with various disease states. Although the two major isozymes have been extensively studied, the structure and biosynthetic origins of the I-forms are unknown. Characterization of a placental hexosaminidase I-form, presented in this report, demonstrates that it is composed of two forms of partially processed hexosaminidase A. The major form contains an intact pro-alpha chain and a pro-beta chain lacking 2 residues from its amino terminus (Ala and Arg). The minor form also contains an alpha and a beta subunit, but each has undergone further proteolytic processing. The amino terminus of each of these partially processed polypeptide chains matches one of those previously found on stable processing intermediates in a single normal human fibroblast cell line. These data confirm that similar processing intermediates exist in human placenta, suggesting that this I-form lacks a unique enzymatic function in vivo. A sequence of normal proteolytic processing events is postulated.
1. An electrophoretic system in which N-acetyl hexosaminidase C (HEX(C)) MIGRATES LESS ANODALLY THAN N-acetyl hexosaminidase A (HEX(A)) is described. 2. HEX(C) is shown to differ from HEX(A) and HEX(B) in substrate specificity, molecular size and affinity for Concanavalin-A. 3. HEX(C) is present in a wide range of adult and foetal tissues and in tissues from patients with Tay-Sachs and Sandhoff's diseases. It is particularly prominent in brain, testis, thymus and lymphoblastoid cell extracts and in several foetal tissues. 4. It is suggested that HEX(C) is coded at a separate gene locus from HEX(A) and HEX(B).
The type and distribution of the oligosaccharides on each polypeptide of human placental beta-hexosaminidases A (alpha (beta a beta b)) and B (2(beta a beta b)) were examined. The denatured polypeptides were separated by isoelectric focussing in a polyacrylamide slab gel and each gel was then overlaid with 125I-labelled lectins. The study indicated that the beta a chain contains negligible carbohydrate, the beta b chain contains both the high-mannose and a complex type oligosaccharide, and the alpha chain contains predominantly high-mannose or hybrid type moieties. Two asparagine-linked high-mannose type oligosaccharides present on the beta b polypeptide of beta-hexosaminidase B were isolated by concanavalin A chromatography and by reverse-phase high pressure liquid chromatography. Proton nuclear magnetic resonance characterization of the oligosaccharides revealed an equimolar glycan mixture of the high-mannose type structure Man5 and Man6.
Hexosaminidase (Hex) BA was prepared from purified placental Hex A by treatment with merthiolate and rechromatography on DEAE Sepharose 6B-CL. The heat stability, isoelectric focussing pattern, and peptide map of this isoenzyme were compared with those of naturally occurring purified placental Hex B. Hex BA proved to be less heat stable at 60 degrees C, have a slightly lower pI, and have one more peptide spot than did Hex B. The lower pI of Hex BA is not caused by sialic acid residues since it was unaffected by neuraminidase treatment. The extra peptide spot in the Hex BA map cannot be explained by carbohydrate differences since no corresponding unpaired peptide spot was seen in the Hex B map. Though Hex B and BA are products of the same gene, there is evidence that both are derived from a larger precursor polypeptide chain. Our results indicate that Hex B and BA are processed differently resulting in a small peptide present in Hex BA that is not found in Hex B.
Normal human skin fibroblasts secrete most of their hexosaminidase (Hex) into the medium upon incubation with 10(-4) imipramine, while preincubation with 2.5 X 10(-9) M dexamethasone prevents this effect. These results support the hypotheses that 1) treatment of psychotic Hex A deficient patients with amphiphilic antidepressants (such as imipramine) aggravates the patients' disease through depletion of their residual cellular Hex A, and 2) concomitant medication with dexamethasone may mitigate this drug-induced deleterious effect.
Data from a mass screening program for identification of persons who are heterozygous for Tay-Sachs disease have been analyzed for the effects of oral contraceptive steroids on the activity in serum of hexosaminidase (hex) and the various hex isozymes. Women using oral contraceptives show a significantly higher total serum hex activity, reflecting mainly an increase in the heat-stable hex isozyme (hex I), and a smaller increase in the heat-labile hex A than do women using no medications. The changes in women using oral contraceptives are qualitatively similar to those observed during pregnancy. The distribution of responses to oral contraceptives is unimodal, and some of the variations may be related to differences in amount of steroid ingested. In addition, underlying genetic variation may contribute to the observed differences in enzyme activities.
A family (father and daughter) was found with a deficiency of hexosaminidase (HEX A and HEX B). Residual HEX A activity was about 30% of usual heterozygotes with very little HEX B activity. Thermostability of HEX A was decreased. No immunological cross reacting material was found for HEX A or B. The mechanism seems to be the production of abnormal, unstable beta subunits, which are still capable of combining with alpha subunits to form functional HEX A.
Hexosaminidase isoenzymes P from serum of pregnant women and I2 from serum of leukemic children were compared using various biochemical methods, namely, ion exchange chromatography, isoelectric focusing, and molecular weight determination by gel filtration. Isoenzyme I2 is activated by calcium, magnesium, and manganese. The molecular weight of isoenzyme I2 was 110,000 compared to 130,000 of isoenzyme P. The widely differing molecular weights exclude the so far suggested identity of both enzymes. Both isoenzyme P and isoenzyme I2 possess beta-chains, however, they differ in chain structure and glycosylation. This different structure of isoenzyme P may be one of the reasons for its increase during pregnancy due to the resulting impaired clearance by liver sinusoidal cells.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.